S100A4 Antibody

1. ERRgamma may exert oncogenic activity mainly associated with aggressiveness of EC by activating S100A4 transcription. PMID: 29901152
2. S100A4 expression is induced by the TGF-beta pathway,. PMID: 29141874
3. This meta-analysis showed that overexpression of S100A4 seems to be associated with tumor progression and poor prognosis of PC patients. PMID: 29578167
4. clusterin promotes growth and invasion in renal cell carcinoma cells in vitro and in vivo through upregulation of S100A4 PMID: 29400663
5. miR-3189-3p mimics enhanced the effects of the S100A4 siRNA on the inhibition of gastric cancer cell proliferation and migration by targeting CFL2. PMID: 29342841
6. Urine S100A4 shows the most promise as an lupus nephritis (LN) activity biomarker. PMID: 29065913
7. S100A4 is up-regulated in cervical adenocarcinomas and squamous cell carcinomas. PMID: 28921916
8. Network analysis of overlapping genes revealed the effects on tubulins (Tubb2a, Tubb3, Tubb4b), Nfe2l2, S100a4, Cd44, and Nfkb2, all of which are linked to TBI-relevant outcomes, including epileptogenesis and tissue repair PMID: 27530814
9. Authors first provide experimental evidence suggesting that FAM107B was downregulated by S100A4 in gastric cancer MGC803 cells. And FAM107B at least partially mediates the biological effect of S100A4 in the cells. PMID: 28675500
10. MiR-187 could interact with S100A4 3'-UTR. PMID: 29303365
11. Both the calcium-binding ability and the C-terminal region of S100A4 are important for cancer initiatin cells to sustain their stemness properties and malignancy in head and neck cancers. PMID: 27793047
12. Studied the role and expression of MIR296 in the metastasis and epithelial-mesenchymal transition of colorectal cancer. Found MIR296 inhibited migration and invasion of tumor cells, as well as suppressed S100A4 abundance in tumor cells. PMID: 28209128
13. S100A4-expression was associated with poor outcome in early-stage breast cancer, but the low percentage of positive tumors and the modest survival differences imply that the clinical utility in selection of patients for adjuvant treatment is limited. PMID: 28058579
14. The relative expression of S100A4 mRNA was higher when mod-SHEM was used, although significant differences were detected only when the expression levels were compared with those found in LPCs incubated with IOBA-FBS PMID: 27911610
15. High S100A4 expression is associated with Mesenchymal Transition in Glioblastoma. PMID: 28807938
16. our findings demonstrate that S100A4 is post-transcriptionally regulated by tumor suppressor microRNAs PMID: 28423501
17. findings indicate that Idiopathic pulmonary fibrosis mesenchymal progenitor cells are intrinsically fibrogenic and that S100A4 confers mesenchymal progenitor cells with fibrogenicity. PMID: 28530639
18. S100a4 is expressed in a limited number of stromal cells throughout the colon. S100A4 was mainly localised in the colorectal tumour-associated stroma, it was also detectable in a limited number of epithelial tumour cells. PMID: 27750112
19. our results suggest the existence of evolutionarily conserved pathways used by S100A4 to promote metastatic dissemination PMID: 27927689
20. miR-187-3p inhibits the migration/metastasis and epithelial mesenchymal transition in hepatocellular carcinoma by targeting S100A4 expression. PMID: 27544906
21. our findings highlight nuclear S100A4 as a candidate therapeutic target in cholangiocarcinoma and establish a mechanistic rationale for the use of low-dose paclitaxel in blocking metastatic progression of cholangiocarcinoma PMID: 27328733
22. The increased content of collagen fibers and overexpression of S100A4 and P53 may play an important role in myocardial fibrosis of HCM, and they can be used in future HCM research. Blockade of S100A4 may have therapeutic potential in HCM by attenuating cardiac fibrosis. PMID: 26781584
23. The experimental and in silico results suggest two divergent evolutionary pathways: NMIIA and NMIIB evolved to possess S100A4-dependent and -independent regulations, respectively. PMID: 27029887
24. Results found that CNE-1 nasopharyngeal carcinoma cell (NPC) line expressing S100A4 showed significantly increased invasion ability in vitro and in vivo. Also, it seems that aberrant DNA hypomethylation of its promotor region might lead to the metastasis progression in EBV-associated NPC. PMID: 26292668
25. Oct-1 modifies S100A4 exchange between intra- and extracellular compartments in Namalwa cells and increases their sensitivity to glucocorticoids. PMID: 27096393
26. ChIP studies showed that the S100A4 protein binds to the GDF15 promoter, implicating S100A4 in GDF15 regulation at the transcriptional level. PMID: 27278086
27. Cell invasion (matrigel) was reduced only in the Hs578T cells (p < 0.01). Silencing decreased the expression of the prometastatic molecules S100A4 and TGFbetaR2 in both cell lines and CD44 in Hs578T cells .We conclude that ECM1 is a key player in the metastatic process and regulates the actin cytoskeletal architecture of aggressive breast cancer cells at least in part via alterations in S100A4 and Rho A. PMID: 27770373
28. Aberrant S100A4 expression may predictendometrial cancer (EC) progression and play an important role in regulating EC cell invasion through Epithelial-mesenchymal transition (EMT) regulation. PMID: 27109209
29. S100A4 could promote the invasion ability of breast cancer cells via EMT, more importantly, it could participate in EMT via regulating MMP2 in breast cancer. PMID: 26409452
30. our results demonstrate not only that high expression of S100A4 contributes to an aggressive phenotype of EC, but also that its elevated expression is closely related to the MELF histopathological pattern. PMID: 27348205
31. S100A4, A8, and A9 proteins represent promising marker genes to evaluate the risk potential of suspicious oral lesions in molecular pathology. PMID: 27294692
32. Increased S100A4 expression is associated with thyroid papillary carcinoma. PMID: 26715280
33. Comparative analysis of various tumor lines showed no clear correlation between the expression level of Mts1/S100A4 and the content of Oct-1. However, at stable transfection of tumor cells with Oct-1A, Oct-1L, and Oct-1X isoforms we detected an elevated level of Oct-1, which stimulated Mts1/S100A4 secretion. PMID: 27193714
34. We studied the expression of S100A4 and the total PHF10 protein in some human cancer cell lines. We have found that, in the cell lines studied, the PHF10 expression is correlated with the S100A4 expression. PMID: 27193724
35. These results support the hypothesis that S100A4 contributes significantly to growth and metastasis, and that down-regulation of S100A4 expression decreases the metastatic potential of ATC cells. PMID: 27802204
36. Interaction of extracellular S100A4 with RAGE prompts prometastatic activation of melanoma cells. PMID: 26928771
37. Study shows that negative expression of S100A4 was significantly associated with higher 3-year OS rate and N0 stage for lymph node metastasis in pancreatic neoplasm tumor which suggest that S100A4 expression represents a potential marker for lymph node metastasis and a potential unfavorable factor for prognosis of patients with this disease. PMID: 26903691
38. S100A4 mRNA level is an important molecular biomarker for prediction of chemosensitivity to gemcitabine in unresectable pancreatic cancer. PMID: 26722531
39. Tag7-Mts1 complex causes chemotactic migration of lymphocytes, with NK cells being a preferred target. PMID: 26654597
40. our data suggest a novel mechanism for mutant p53V143A accumulation and add a new facet to the role of S100A4 in cancer PMID: 26497012
41. S100A4 levels are elevated in human periodontal ligament cells in response to IL-1beta. PMID: 26499072
42. Enhanced S100A4 expression was observed in remodeled intrapulmonary arteries of COPD patients. PMID: 26483185
43. Downregulation of AKT3 increases migration and metastasis in triple negative breast cancer cells by upregulating S100A4. PMID: 26741489
44. vimentin and FSP1 have roles in gingival fibrosis PMID: 25826487
45. Through selective knockout or inhibition of the network components, we show that the interaction between epidermal growth factor receptor (EGFR) and S100A4 modulates the sensitivity of angiogenesis development to matrix metalloproteinases (MMPs) activity PMID: 26057862
46. The results show that S100A4 enhances the activity of matrix metalloproteinases (MMPs), causing higher cell dissociation. Moreover, it leads to an increased stability of the pathological state. PMID: 26118552
47. EZH2 mediates the regulation of E-cadherin expression by S100A4 and controls the proliferation and migration of gastric cancer cells. PMID: 26897964
48. Proximity ligation assay demonstrate proximity between S100A4 and cyclin B1 in vitro, while confocal microscopy showed S100A4 to localize to areas corresponding to centrosomes in mitotic cells prior to chromosome segregation. PMID: 26349943
49. Elevated S100A4 in plasma is a novel biomarker for early detection of acute myocardial infarction. PMID: 26166646
50. PTCSC3 downregulates S100A4, leading to a reduction in cell motility and invasiveness. We propose that PTCSC3 impacts papillary thyroid cancer predisposition and carcinogenesis through the S100A4 pathway. PMID: 26274343

Show More

Hide All

HGNC: 10494

OMIM: 114210

KEGG: hsa:6275

STRING: 9606.ENSP00000346294

UniGene: Hs.654444